CLBT — Cellebrite DI Cashflow Statement

0.000.00%

Last trade - 00:00

TechnologyBalancedLarge CapHigh Flyer

Annual cashflow statement for Cellebrite DI, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	20-F	20-F	20-F
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	5.78	71.4	121	-81.1	-283
Depreciation
Deferred Taxes
Non-Cash Items	7.96	-61.4	-104	130	367
Other Non-Cash Items
Changes in Working Capital	49.7	20.7	-2.82	38.5	42
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	66.5	36.1	20.6	102	132
Capital Expenditures	-6.18	-8.11	-9.09	-7.92	-10.6
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-0.268	53.3	-82.1	-14.6	-139
Acquisition of Business
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Cash from Investing Activities	-6.45	45.2	-91.2	-22.5	-149
Financing Cash Flow Items	0	29.3	0	0	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Cash from Financing Activities	-8.59	-68.4	14	21.8	20.7
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	52.2	12.1	-58.3	102	2.14